UNITY Biotechnology Debt to Equity Ratio 2017-2025 | UNBX
Current and historical debt to equity ratio values for UNITY Biotechnology (UNBX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. UNITY Biotechnology debt/equity for the three months ending March 31, 2025 was 0.00.
| UNITY Biotechnology Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2025-03-31 |
$0.03B |
$0.00B |
-149.03 |
| 2024-12-31 |
$0.03B |
$0.01B |
4.80 |
| 2024-09-30 |
$0.03B |
$0.01B |
2.33 |
| 2024-06-30 |
$0.03B |
$0.02B |
1.71 |
| 2024-03-31 |
$0.04B |
$0.02B |
1.45 |
| 2023-12-31 |
$0.04B |
$0.03B |
1.31 |
| 2023-09-30 |
$0.03B |
$0.04B |
0.91 |
| 2023-06-30 |
$0.05B |
$0.05B |
1.04 |
| 2023-03-31 |
$0.06B |
$0.06B |
0.95 |
| 2022-12-31 |
$0.07B |
$0.06B |
1.22 |
| 2022-09-30 |
$0.06B |
$0.08B |
0.74 |
| 2022-06-30 |
$0.06B |
$0.04B |
1.44 |
| 2022-03-31 |
$0.06B |
$0.05B |
1.22 |
| 2021-12-31 |
$0.07B |
$0.06B |
1.09 |
| 2021-09-30 |
$0.07B |
$0.06B |
1.18 |
| 2021-06-30 |
$0.07B |
$0.07B |
1.07 |
| 2021-03-31 |
$0.07B |
$0.08B |
0.85 |
| 2020-12-31 |
$0.07B |
$0.08B |
0.89 |
| 2020-09-30 |
$0.08B |
$0.10B |
0.78 |
| 2020-06-30 |
$0.05B |
$0.11B |
0.47 |
| 2020-03-31 |
$0.05B |
$0.11B |
0.50 |
| 2019-12-31 |
$0.03B |
$0.12B |
0.25 |
| 2019-09-30 |
$0.03B |
$0.12B |
0.24 |
| 2019-06-30 |
$0.03B |
$0.13B |
0.21 |
| 2019-03-31 |
$0.01B |
$0.15B |
0.10 |
| 2018-12-31 |
$0.02B |
$0.16B |
0.13 |
| 2018-09-30 |
$0.02B |
$0.18B |
0.09 |
| 2018-06-30 |
$0.01B |
$0.20B |
0.07 |
| 2018-03-31 |
$0.01B |
$0.13B |
0.11 |
| 2017-12-31 |
$0.01B |
$0.09B |
0.12 |
| 2017-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2017-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2017-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2016-12-31 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.002B |
$0.000B |
|
UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company's product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States.
|
